肺癌化疗前后肿瘤标记物变化及其意义

Initial Investigation of Tumor Markers Changing in Chemotherapeutics among Lung Cancer Patients

目的 探讨化疗前后肿瘤标记物变化对于肺癌化疗效果评价的价值。方法 2 0例肺癌经 3个疗程的VAP方案化疗 ,监测第 1次化疗前和第 3次化疗后肿瘤标记物 AFP、CEA、CA5 0、CA19- 9、CA12 5、CA15 3、CA2 4 2、SCC及 NEC的变化。结果 3次化疗后 CA5 0和 CA12 5水平较化疗前减低 ,其中 CA5 0对于小细胞肺癌 ,CEA对于肺腺癌化疗后效果的评定具有一定价值。而化疗后 CA12 5的减低与肿瘤分类关系不大。结论 通过监测肿瘤标记物 CEA、CA5 0和 CA12 5水平改变可以协助肺癌化疗后疗效的判断 ,具有简便、经济的特点 ,在临床中具有一定的价值。

Objective To investigate the role of tumor markers’ changing in evaluation of effects of chemotherapeutics among lung cancer patients.Methods Twenty lung cancer patients were confirmed by pathology through surgery. All patients were given 3 periods of chemotherapy by projecting VAP (VDS+ADR+DDP) before the first and after the third chemotherapy. We registered the tumor markers’ alteration of AFP, CEA, CA50, CA19-9, CA125, CA153, CA242, SCC and NEC. Results After the third chemotherapy the changes of CA50 and CA125 apparently reduced, which were statistically significant different from the value of the first chemotherapy. The values of CA50 reduction with small cell lung cancer and CEA with lung adenocarcinoma had significant clinical values.Conclusion Combined Monitoring on CEA, CA50 with CA125 could help evaluate the effects of post-chemotherapy, which is simple and cost-effective.